-
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics (ADAP) Prices 21 Million Offering at $4/ADS
-
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
-
Roth Capital Starts Adaptimmune Therapeutics plc (ADAP) at Buy

